BioSig Technologies (BSGM) Financials
Newest figures come from the 10-Q for Q1 FY2026, filed May 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BSGM SEC filings page.
This page shows BioSig Technologies, Inc. (BSGM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 shows a business financed through balance-sheet expansion, with a large reported loss but far smaller operating cash outflow.
The earnings-to-cash gap is unusually wide: FY2025 reported a net loss of$462.8M alongside operating cash flow of-$10.4M . The positive financing cash flow of$54.9M coincided with total assets reaching$187.5M , so reported expansion was associated with financing flows rather than operating cash generation.
Compared with FY2024, FY2025 moved from negative equity of
FY2025’s reported cost structure was dominated by SG&A at
Financial Health Signals
BioSig Technologies, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
BioSig Technologies, Inc. passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 3 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
BioSig Technologies, Inc. reported a net loss of $462.8M while operations used $10.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
BioSig Technologies, Inc. reported an operating loss of $71.1M against $1.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
BioSig Technologies, Inc.'s EBITDA was -$34.3M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
BioSig Technologies, Inc. reported a net loss of $46.7M in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Not reported for Q1 2026.
Cash & Balance Sheet
BioSig Technologies, Inc. held $6.9M in cash as of Q1 2026; no long-term debt figure is on record for that period.
Not reported for Q1 2026.
Not reported for Q1 2026.
Margins & Returns
BioSig Technologies, Inc.'s quarterly ROE was -29.4% in Q1 2026: one quarter's net income over shareholder equity, not annualized. This is up 78.6 percentage points from the same quarter a year earlier.
Not reported for Q1 2026.
Not reported for Q1 2026.
Not reported for Q1 2026.
Capital Allocation
BioSig Technologies, Inc. invested $6K in research and development in Q1 2026. That is unchanged from the same quarter a year earlier.
Not reported for Q1 2026.
Not reported for Q1 2026.
BSGM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $13Kn/m |
| R&D Expenses | $6K0.0% | N/A | $6K-96.2% | $19K-94.4% | $6K-97.5% | N/A | $156K-86.4% | $342K-80.0% |
| SG&A Expenses | $34.3M+1058.4% | N/A | $4.6M+67.2% | $19.8M+302.8% | $3.0M+2.6% | N/A | $2.8M-1.8% | $4.9M-46.0% |
| Operating Income | -$35.7Mn/m | N/A | -$6.1Mn/m | -$20.4Mn/m | -$3.0Mn/m | N/A | -$3.0Mn/m | -$5.3Mn/m |
| EBITDA | -$34.3Mn/m | N/A | -$4.6Mn/m | -$19.8Mn/m | -$3.0Mn/m | N/A | -$2.9Mn/m | -$5.2Mn/m |
| Interest Expense | $12.2M | N/A | -$10K | $13Kn/m | N/A | N/A | N/A | -$5K-266.7% |
| Income Tax | -$565K | N/A | -$765K | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$46.7Mn/m | N/A | -$15.6Mn/m | -$20.4Mn/m | -$2.8Mn/m | N/A | -$1.9Mn/m | -$3.9Mn/m |
| EPS (Basic) | -$0.27 | N/A | -$0.47 | -$0.74 | -$0.14 | N/A | -$0.12 | -$0.30 |
| EPS (Diluted) | -$0.27 | N/A | -$0.47 | -$0.74 | -$0.14 | N/A | -$0.12 | -$0.30 |
| Diluted Shares (Avg) | 175M | N/A | 33M | 28M | 21M | N/A | 16M | 13M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
BSGM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $173.3M+3823.0% | $187.5M+22173.5% | $130.5M+9104.1% | $109.7M+3431.4% | $4.4M+178.0% | $842K-53.2% | $1.4M-55.0% | $3.1M-23.3% |
| Current Assets | $45.9M+1051.6% | $71.9M+18429.6% | $15.0M+1667.9% | $3.0M+25.8% | $4.0M+438.6% | $388K-26.5% | $848K-19.3% | $2.4M+20.1% |
| Cash & Equivalents | $6.9M+84.0% | $20.3M+14195.8% | $11.0M+1695.9% | $2.8M+34.0% | $3.7M+795.9% | $142K-29.0% | $615K+53.8% | $2.1M+61.8% |
| Accounts Receivable | N/A | N/A | N/A | N/A | $109K+678.6% | $109K+354.2% | $81K+478.6% | $54K+157.1% |
| Goodwill | $69.8M | $71.0M | $69.9M | $58.7M | N/A | N/A | N/A | N/A |
| Total Liabilities | $14.0M+732.1% | $54.2M+2294.7% | $137.3M+7973.8% | $113.2M+3684.7% | $1.7M-71.0% | $2.3M-51.7% | $1.7M-58.6% | $3.0M-17.2% |
| Current Liabilities | $3.3M+96.7% | $42.8M+1790.2% | $125.6M+7283.9% | $113.2M+3703.8% | $1.7M-67.9% | $2.3M-50.6% | $1.7M-56.5% | $3.0M-10.7% |
| Non-Current Liabilities | $10.7Mn/m | $11.4Mn/m | $11.7Mn/m | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $15K-94.7% |
| Total Equity | $159.0M+6003.1% | $133.2Mn/m | -$7.0Mn/m | -$3.6Mn/m | $2.6Mn/m | -$1.5Mn/m | -$405Kn/m | -$6K-102.5% |
| Retained Earnings | -$764.8Mn/m | -$718.1Mn/m | -$294.1Mn/m | -$278.5Mn/m | -$258.2Mn/m | -$255.3Mn/m | -$254.2Mn/m | -$252.3Mn/m |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Long-Term Debt.
BSGM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.2Mn/m | -$3.0Mn/m | -$5.0Mn/m | -$1.3Mn/m | -$1.1Mn/m | -$474Kn/m | -$1.5Mn/m | -$1.5Mn/m |
| Depreciation & Amortization | $1.5M+7004.8% | N/A | $1.5M+4700.0% | $554K+1030.6% | $21K-73.1% | N/A | $31K-66.3% | $49K-46.7% |
| Stock-Based Compensation | $54-100.0% | N/A | N/A | N/A | $2.1M+95.5% | N/A | N/A | N/A |
| Investing Cash Flow | -$1.5M | -$24.5M | -$145K | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | -$1.6M-134.8% | $36.8M+3677900.0% | $13.4Mn/m | $0-100.0% | $4.7M+205.2% | $1K-100.0% | $0-100.0% | $3.2M-34.1% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
BSGM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -40707.7% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -30115.4% |
| Return on Equity | -29.4%+78.6pp | N/A | N/A | N/A | -107.9% | N/A | N/A | N/A |
| Return on Assets | -26.9%+36.7pp | N/A | -11.9%+123.0pp | -18.6%+107.4pp | -63.6%+150.5pp | N/A | -135.0%+9.8pp | -126.0%+147.9pp |
| Current Ratio | 13.90+11.5x | 1.68+1.5x | 0.12-0.4x | 0.03-0.8x | 2.37+2.2x | 0.17+0.1x | 0.50+0.2x | 0.80+0.2x |
| Liabilities-to-Equity | 0.09-0.6x | 0.41 | N/A | N/A | 0.64 | N/A | N/A | N/A |
| Asset Turnover | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.000.0x |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BioSig Technologies, Inc. BSGM | FY2025 | N/A | -$462.8M | N/A | N/A | — |
| CVRx, Inc. CVRX | FY2025 | $56.7M | -$53.3M | -94.1% | $38.0M | 51/100 |
| 908 Devices Inc. MASS | FY2025 | $56.2M | $19.5M | 34.7% | $531.1M | 43/100 |
| Outset Medical, Inc. OM | FY2025 | $119.5M | -$81.7M | -68.3% | $78.8M | 62/100 |
| TriSalus Life Sciences, Inc. TLSI | FY2025 | $45.2M | -$39.2M | -86.9% | $237.7M | 50/100 |
Where BioSig Technologies, Inc. Ranks
Frequently Asked Questions
Is BioSig Technologies, Inc. profitable?
No, BioSig Technologies, Inc. (BSGM) reported a net loss of $462.8M in fiscal year 2025.
What is BioSig Technologies, Inc.'s EBITDA?
BioSig Technologies, Inc. (BSGM) had EBITDA of -$67.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is BioSig Technologies, Inc.'s return on equity (ROE)?
BioSig Technologies, Inc. (BSGM) has a return on equity of -347.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BioSig Technologies, Inc.'s operating cash flow?
BioSig Technologies, Inc. (BSGM) recorded an outflow of $10.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are BioSig Technologies, Inc.'s total assets?
BioSig Technologies, Inc. (BSGM) had $187.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does BioSig Technologies, Inc. spend on research and development?
BioSig Technologies, Inc. (BSGM) invested $31K in research and development during fiscal year 2025.
What is BioSig Technologies, Inc.'s current ratio?
BioSig Technologies, Inc. (BSGM) had a current ratio of 1.68 as of fiscal year 2025, which is generally considered healthy.
What is BioSig Technologies, Inc.'s liabilities-to-equity ratio?
BioSig Technologies, Inc. (BSGM) had a liabilities-to-equity ratio of 0.41 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is BioSig Technologies, Inc.'s return on assets (ROA)?
BioSig Technologies, Inc. (BSGM) had a return on assets of -246.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does BioSig Technologies, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, BioSig Technologies, Inc. (BSGM) held $30.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.4M over that year. Dividing the one by the other, the reported balance equals about 35 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is BioSig Technologies, Inc.'s Piotroski F-Score?
BioSig Technologies, Inc. (BSGM) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BioSig Technologies, Inc.'s earnings high quality?
BioSig Technologies, Inc. (BSGM) reported a net loss of $462.8M while operations used $10.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BioSig Technologies, Inc. cover its interest payments?
BioSig Technologies, Inc. (BSGM) reported an operating loss of $71.1M against $1.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.